NEW OR RETURNING USERS: SIGN IN  |   UPDATE PROFILE  |   CME/CE TRACKER    



  

Oncology

What Pharmacists Need to Know
About Targeted Therapies
This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Oncology.

What Pharmacists Need to Know About Targeted Therapies


Unraveling the Molecular Basis of Cancer (16 Minutes)
An overview of major molecular pathways in cancer development that have been identified as potential targets for successful therapeutic interventions.
    — Hai T. Tran, PharmD

How Do Targeted Therapies Work? (10 Minutes)
An exploration of the mechanism of action of recently FDA-approved and promising investigational targeted agents, with a discussion of target specificity for different solid tumors.
    — Jon D. Herrington, PharmD, BCPS, BCOP

Clinical Update: Efficacy and Safety of Targeted Therapies
(16 Minutes)

A practical analysis of recent efficacy and safety results from clinical trials of FDA-approved and late-stage investigational targeted therapies in the treatment of patients with solid tumors.
    — Cathy Eng, MD

Present and Future Role of Targeted Therapies in Cancer Care (17 Minutes)
A discussion of the evolving role of targeted therapies in the development and implementation of more effective strategies for the care of patients with solid tumors.
    — Tarek Mekhail, MD, MSc, FRCSI, FRCSEd

CHAIR
Hai T. Tran, PharmD
Assistant Professor
Pharmacology – Research Cancer Medicine
  and Pharmacy
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas


FACULTY
Cathy Eng, MD
Assistant Professor
Department of Gastrointestinal Medical Oncology
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Jon D. Herrington, PharmD, BCPS, BCOP
Hematology/Oncology Clinical Specialist
Department of Pharmacy
Scott & White Memorial Hospital
Temple, Texas



Tarek Mekhail, MD, MSc, FRCSI, FRCSEd
Director, Lung Cancer Medical Oncology Program
Hematology/Medical Oncology
The Cleveland Clinic
Cleveland, Ohio
top

TARGET AUDIENCE
What Pharmacists Need to Know About Targeted Therapies will be directed to oncology pharmacists involved in the care of cancer patients.

ACTIVITY GOAL
The goal of What Pharmacists Need to Know About Targeted Therapies is to provide the latest data on the use of targeted therapies in the treatment of solid tumors.

LEARNING OBJECTIVES
  • Differentiate among major cellular signaling pathways involved in cancer development to identify potential targets for therapeutic interventions.

  • Assess how targeted therapies may work in the treatment of various solid tumors utilizing knowledge of the mechanism of action of these agents on cancer growth.

  • Analyze the efficacy and safety of targeted therapies in the treatment of solid tumors based on recent clinical trial results.

  • Evaluate treatment strategies for patients with solid tumors by integrating an understanding of the mechanisms, efficacy, and safety of current and emerging targeted therapies.
top

CE Information: Pharmacists
Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to the program, for 1 contact hour (0.1 CEU) is 052-000-06-021-H01.

Contract for Mutual Responsibility in CME/CE

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CE activity, please see your current Physicians' Desk Reference (PDR).

Cathy Eng, MD, has disclosed that she will reference unlabeled/unapproved use of bevacizumab in clinical trials for breast cancer.

Jon D. Herrington, PharmD, BCPS, is on the speakers bureau of Amgen Inc; his wife is an employee of Pfizer Inc. Dr. Herrington has disclosed that he will not reference any unlabeled/unapproved uses of drugs or devices.

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, has received grant/research support from Celgene Corporation, Genentech, Inc, Merck & Co, Inc, and Vion Pharmaceuticals, Inc; is on the speakers bureau of Genentech, Inc, Eli Lilly and Company, and Sanofi-Aventis; and owns stock in Genentech, Inc and Pfizer Inc. Dr. Mekhail has disclosed that he will reference unlabeled/unapproved uses of bevacizumab.

Hai T. Tran, PharmD, has received grant/research support from AstraZeneca, Genetnech, Inc, Novartis Pharmaceuticals Corporation, and OSI Pharmaceuticals Inc; is a consultant for Genentech, Inc; and is on the speakers bureau of Genentech, Inc and Sanofi-Aventis. Dr. Tran has disclosed that he will not reference any unlabeled/unapproved uses of drugs or products in his presentation.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.


This independent CE activity is supported by an educational grant from Genentech, Inc and OSI Oncology.
top

1775

 

 

Program Information

Faculty
Target Audience
Activity Goal
Learning Objectives
CME Information
Disclosure Information
Technical Requirements


By clicking below, I certify that I have read the accompanying CE and disclosure information and am ready to continue to this activity.

Release Date: October 23, 2006.
Termination Date: October 23, 2007.
Estimated Time for Completion of this Activity: 1 hour.

There is no fee for this activity.



Recommend this page
Recommend this to a colleague


This independent CE activity is supported by an educational grant from Genentech, Inc and OSI Oncology.




ABOUT US  |  CONTACT US  |  CONTRACT  |  DIRECTIONS  |  PRIVACY POLICY  |  RESOURCES
Copyright © 1997-2017, Projects In Knowledge, Inc. All rights reserved.
PROJECTS IN KNOWLEDGE • Overlook at Great Notch • 150 Clove Road, 10th Floor • Little Falls, New Jersey 07424 (973) 890-8988